In addition to the reports of the efficacy of PARP and tubulin in endometrial cancer (monotherapy), some precedents advocate for a more pronounced efficacy of a combination of PARP and tubulin inhibitors ascertaining the benefits of simultaneous modulation of both targets. The gene discussed is PARP1; the disease is endometrial cancer.